MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer

BACKGROUND: Cisplatin is widely used as a first-line treatment for non-small cell lung cancer (NSCLC), but chemoresistance remains a major clinical obstacle for efficient use. As a microRNA, miR-223 was reported to promote the doxorubicin resistance of NSCLC. However, whether miR-223 is also involve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell Int
Main Authors: Wang, Hui, Chen, Jiabin, Zhang, Shufen, Zheng, Xiaoxiao, Xie, Shangzhi, Mao, Jiayan, Cai, Ying, Lu, Xuemei, Hu, Liqiang, Shen, Jian, Chai, Kequn, Chen, Wei
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Primary Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7304223/
https://ncbi.nlm.nih.gov/pubmed/32577098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01284-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados